- Home
- SKWD vs SUPN Comparison
SKWD vs SUPN Comparison
Compare SKWD & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKWD
- SUPN
- Stock Information
- Founded
- SKWD 2007
- SUPN 2005
- Country
- SKWD United States
- SUPN United States
- Employees
- SKWD N/A
- SUPN 674
- Industry
- SKWD Property-Casualty Insurers
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- SKWD Finance
- SUPN Health Care
- Exchange
- SKWD Nasdaq
- SUPN Nasdaq
- Market Cap
- SKWD 2.3B
- SUPN 2.5B
- IPO Year
- SKWD 2023
- SUPN 2012
- Fundamental
- Price
- SKWD $50.23
- SUPN $46.00
- Analyst Decision
- SKWD Buy
- SUPN Buy
- Analyst Count
- SKWD 11
- SUPN 2
- Target Price
- SKWD $63.78
- SUPN $43.00
- AVG Volume (30 Days)
- SKWD 383.2K
- SUPN 809.3K
- Earning Date
- SKWD 10-28-2025
- SUPN 11-03-2025
- Dividend Yield
- SKWD N/A
- SUPN N/A
- EPS Growth
- SKWD 6.84
- SUPN 1411.53
- EPS
- SKWD 3.16
- SUPN 1.14
- Revenue
- SKWD $1,253,720,000.00
- SUPN $665,125,000.00
- Revenue This Year
- SKWD $17.46
- SUPN $4.84
- Revenue Next Year
- SKWD $11.77
- SUPN $17.69
- P/E Ratio
- SKWD $15.90
- SUPN $40.09
- Revenue Growth
- SKWD 21.67
- SUPN 5.55
- 52 Week Low
- SKWD $37.79
- SUPN $29.16
- 52 Week High
- SKWD $65.05
- SUPN $46.08
- Technical
- Relative Strength Index (RSI)
- SKWD 52.02
- SUPN 73.94
- Support Level
- SKWD $48.01
- SUPN $44.10
- Resistance Level
- SKWD $54.00
- SUPN $45.94
- Average True Range (ATR)
- SKWD 1.25
- SUPN 1.10
- MACD
- SKWD 0.41
- SUPN -0.13
- Stochastic Oscillator
- SKWD 43.14
- SUPN 97.91
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.